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Summary
No antiepileptic drug is completely safe to use 
in pregnancy as the risk of fetal abnormality is 
increased. Valproate should be avoided if possible 
because of the risk of major malformations. 
Ideally a plan for managing the woman's epilepsy 
during pregnancy should be prepared before 
conception. The occurrence of an unexpected 
pregnancy should not trigger sudden cessation or 
alteration of antiepileptic drug treatment without 
medical advice. The smallest effective dose of 
a drug with a low risk of teratogenicity should 
be used. Doses may need adjustment as the 
pharmacokinetics of some drugs change during 
pregnancy. Data are limited, but most antiepileptic 
drugs seem to have little effect on full-term 
breastfed babies.
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Introduction
Uncontrolled epilepsy in a pregnant woman is a serious and 
potentially life-threatening condition for both mother and 
child. Most pregnant women with epilepsy will need to take 
at least one antiepileptic drug. The goal for all concerned is 
a healthy, seizure-free mother and an undamaged child. The 
following somewhat contradictory issues need to be considered 
concurrently.
•	 The optimum treatment of the mother's epilepsy requires 
that the most appropriate antiepileptic drug be used 
in effective doses throughout pregnancy. This requires 
knowledge of specific epileptic syndromes and also 
antiepileptic drug pharmacokinetics before, during and after 
pregnancy.
•	 Any adverse effect that the antiepileptic drug could have 
on the developing child needs to be avoided or minimised 
during pregnancy and lactation.
Fetal abnormality
Women with epilepsy taking antiepileptic drugs have a greater 
(2–3 times) risk than other women of having a baby with a fetal 
abnormality. Taking more than one antiepileptic drug carries a 
higher risk than monotherapy. Major malformations, such as 
congenital heart disease, neural tube defects, urogenital defects 
and cleft lips or palates, occur in about 3–7% of women with 
epilepsy who take antiepileptic drugs, although a substantially 
higher risk is attributed to high doses of valproate (greater than 
1400 mg/day). 
For more than 30 years, a gradually increasing body of 
literature has attributed a 'fetal anticonvulsant syndrome' and 
increased malformation rate to all the 'old' antiepileptic drugs 
– barbiturates, phenytoin, carbamazepine and valproate. Some 
data are now available for lamotrigine, but very little is known 
of the risk of the 'new' antiepileptic drugs such as levetiracetam, 
topiramate, oxcarbazepine, gabapentin, pregabalin, tiagabine 
and zonisamide. 
Problems may emerge in childhood. Numerous small studies 
have suggested cognitive and language impairment and an 
increase in autistic spectrum disorder in children who have been 
exposed to antiepileptic drugs in utero.1 Recent reports suggest 
that these problems may be highest in children who have been 
exposed to valproate. 
In order to better understand the extent of the teratogenic risks 
of all antiepileptic drugs, observational pregnancy registers 
have been established around the world including Australia.* 
These registers contain useful information about the most 
commonly used antiepileptic drugs. From these registers, 
consistent warnings about the increased risk of structural birth 
defects have been issued for valproate. The North American 
Pregnancy Register has published specific concerns with respect 
to phenobarbitone and lamotrigine.
management of women with epilepsy
Before conception, a comprehensive management plan is 
desirable. The diagnosis of epilepsy needs to be validated, 
the epilepsy syndrome elucidated, 'optimal' antiepileptic drug 
treatment established and folate supplements given. Potential 
parents should understand that there are no 'safe' antiepileptic 
drugs in pregnancy. The balance of risks, as presently known, 
should be explained to them. All risk of harm cannot be 
eliminated. 
Women with epilepsy who are considering pregnancy should 
be treated with the least teratogenic but most efficacious 
* Australian Pregnancy Register for women on anti-epileptic 
medication. Phone 1800 069 722.  
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antiepileptic drug for their particular type of epilepsy at the 
lowest effective dose. Pregnancy counselling and planning are 
strongly advised. When an unexpected pregnancy happens and 
embryogenesis has already occurred, there is usually little to 
gain and there may be substantial risk in stopping or changing 
antiepileptic drugs. Early monitoring for an adverse fetal 
outcome and appropriate counselling are advisable.
Folate and vitamin K1
All women are recommended to take folate supplements before 
pregnancy. It is reasonable practice to recommend routine folate 
supplementation, 0.5–1.0 mg/day, to all potentially reproductive 
women with epilepsy taking antiepileptic drugs even if they are 
not contemplating pregnancy. It is currently recommended that 
a woman with epilepsy takes folate 5 mg/day for three months 
before conception and for at least the duration of the first 
trimester. There is good evidence that folate supplementation 
reduces the risks of spina bifida and other malformations in 
large population studies, but there is no documented evidence 
that it further reduces teratogenic risk in women taking 
antiepileptic drugs.
National Health and Medical Research Council Guidelines (2000) 
recommend that all babies at birth are given 1 mg intramuscular 
vitamin K1 or a course of oral vitamin K1. Maternal oral vitamin K1, 
for example 10 mg/day for one month prepartum, has been 
recommended when enzyme-inducing antiepileptic drugs are 
prescribed because the drugs may potentially predispose the 
baby to haemorrhagic disease of the newborn. However, reports 
suggest that this risk is practically negligible.2 
Specific epilepsy syndromes
Two major groups of epilepsies need to be distinguished 
because they typically respond differently to different drugs. 
Localisation-related or partial epilepsies respond to most 
antiepileptic drugs. For idiopathic generalised epilepsy 
valproate is usually the most effective drug. Often, especially 
in juvenile myoclonic epilepsy, seizures can be controlled with 
a reasonably low valproate dose, for example 800 mg/day or 
less. Lamotrigine may be helpful but often is not as effective 
as valproate and sometimes worsens the myoclonic seizures 
of juvenile myoclonic epilepsy. Topiramate and levetiracetam 
may be effective in idiopathic generalised epilepsy while 
carbamazepine, tiagabine, oxcarbazepine, phenytoin and 
gabapentin may worsen some seizure types, especially 
myoclonic and absence seizures. For some women with 
idiopathic generalised epilepsy syndromes, there may be no 
effective alternative to valproate. 
Drug exposure and effects
The pharmacokinetics of antiepileptic drugs may change in 
pregnancy. Doses have to balance the risk of seizures with 
minimising the risk of harming the fetus.
Valproate
Four pregnancy registers and numerous smaller studies have 
warned that there is a substantial risk of major malformations 
including spina bifida when valproate is used as monotherapy 
or with other drugs. The Australian Pregnancy Register3 
has reported the risk to be as high as 16% for first trimester 
fetal exposure to valproate at doses above 1400 mg/day, 
compared with 6% at doses below 1400 mg/day. Others have 
reported higher risk when plasma valproate concentrations 
are consistently high (more than 70 mg/L). Valproate should 
therefore be avoided in reproductive women wherever possible. 
When it is unavoidable, the lowest effective dose should be 
used. It should not exceed 1000 mg/day in divided doses. 
The woman needs to be warned of the risk of seizures and 
she should avoid seizure triggers such as sleep deprivation. 
While she is taking a reduced dose she may have to restrict her 
driving. 
If the valproate dose has been reduced to a minimum during 
pregnancy in order to reduce teratogenesis, the prepartum 
effective dose may need to be re-established before the onset 
of labour. This is a time of increased seizure risk especially in 
patients with idiopathic generalised epilepsy who are very 
sensitive to sleep deprivation. 
Breastfeeding is considered compatible with valproate therapy. 
Valproate concentrations in breastfed babies are low.
Lamotrigine
The North American Pregnancy Register has reported that 
exposure to lamotrigine in the first trimester may cause an 
increased risk of oral clefts (a rate of 8.9 per 1000, as compared 
to 0.37 per 1000 in the reference population).4 Significant dose-
related teratogenesis with lamotrigine exceeding 200 mg/day 
has been reported.5 
Lamotrigine clearance increases steadily through to 32 weeks 
of pregnancy. Plasma concentrations of lamotrigine fall early 
in pregnancy so dose increases may be necessary to control 
seizures. A trough plasma lamotrigine concentration before 
pregnancy, at the onset of the second trimester of pregnancy 
and every two months during pregnancy may help to guide 
any necessary increase in lamotrigine dose. Postpartum, the 
lamotrigine concentration rises within a few days and prompt 
dose reduction may be required to prevent toxicity.6 
Lamotrigine is excreted in considerable amounts into breast 
milk. Early reports show that most full-term babies seem to 
have little problem with breastfeeding, but close monitoring for 
toxicity, especially in small or preterm babies, is advised.
Carbamazepine 
For almost 20 years reports have associated carbamazepine 
with an increased risk of structural birth defects including 
spina bifida. However, no pregnancy register has yet shown 
any statistically significant increase in risk relative to the 
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total population. In the Australian Pregnancy Register, the 
malformation rate with carbamazepine cannot be distinguished 
from that of women with epilepsy who are not taking 
antiepileptic drugs. 
Modest pharmacokinetic changes occur during late pregnancy, 
but dose changes are not usually required. Carbamazepine is 
compatible with breastfeeding in the full-term infant.
Phenytoin
Phenytoin is now used less frequently in women with 
epilepsy. It has been reported to produce an increase in major 
malformations. 
A marked increase in the clearance of phenytoin in pregnancy is 
associated with a fall in plasma concentrations and possible loss 
of seizure control. Regular monitoring of plasma concentrations 
throughout pregnancy helps to determine when a higher dose 
is required. Postpartum monitoring helps prevent phenytoin 
toxicity. The pharmacokinetic changes of early pregnancy 
and postpartum occur more slowly with phenytoin than with 
lamotrigine. Breastfeeding is acceptable with phenytoin. 
Levetiracetam
Levetiracetam has been used in few pregnancies. Its teratogenic 
risk is unknown. 
There appears to be a substantial increase in clearance during 
pregnancy and an associated fall of blood concentrations.7 It is 
not yet known if this is associated with a loss of epilepsy control. 
Serum monitoring is not currently available, but may prove 
helpful in clinical practice. 
Although levetiracetam is secreted into breast milk, recent data 
suggest that the neonatal concentrations are low. Breastfeeding 
is probably acceptable in full-term neonates, but close clinical 
monitoring is advisable.
Clonazepam
Clonazepam is used as an adjunctive antiepileptic drug. No 
particular pregnancy risks have been associated with it, but it 
may cause drowsiness in the breastfed neonate. Withdrawal 
effects can occur if breastfeeding ceases suddenly.
Oxcarbazepine, topiramate, ethosuximide
Only a few pregnancies have been documented, so the 
teratogenic risks of these drugs are unknown. Oxcarbazepine 
clearance seems to increase significantly in pregnancy, but the 
clinical importance of this is uncertain. 
These drugs are excreted in breast milk, but the very limited data 
available suggest that neonatal drug concentrations are usually 
low. Breastfeeding is probably acceptable with clinical monitoring.
Phenobarbitone 
Phenobarbitone is rarely used now in Australia in reproductive 
women with epilepsy. The North American Pregnancy Register 
suggests that it may carry a significant teratogenic risk. A marked 
increase in plasma clearance occurs in pregnancy. Phenobarbitone 
in breast milk may cause neonatal drowsiness and apathy.
Conclusion
In women with epilepsy treated with antiepileptic drugs, there 
is a better than 90% chance that the child will be normal. The 
most specific therapeutic dilemma and the highest risk is in 
women who need to take valproate to control their epilepsy. 
Most infants whose mothers are taking antiepileptic drugs can 
be successfully breastfed without complications.
Editorial note: Some antiepileptic drugs are used in the 
management of bipolar disorders. See: Sved Williams A. 
Antidepressants in pregnancy and breastfeeding. Aust Prescr 
2007;30:125–7. 
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Self-test questions
The following statements are either true or false  
(answers on page 83)
5. Valproate increases the risk of spina bifida if taken during 
pregnancy.
6. The dose of lamotrigine may need to be increased during 
pregnancy.
